This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).

To evaluate the efficacy and safety of 1% tolnaftate formulations delivered through novel stick-based vehicles in the treatment of subjects with potassium hydroxide (KOH)-positive tinea pedis.

Inclusion Criteria:

• Male or female, aged 16 or above
• Clinical diagnosis of tinea pedis (For Cohort 4, positive symptomology is acceptable)
• Confirmation of diagnosis with positive potassium hydroxide (KOH) microscopy (For Cohort 4, a negative KOH test is acceptable)
• Signed and dated informed consent form
• Willingness to comply with study protocol and availability for the duration of the study

Exclusion Criteria:

• Diagnosis of moccasin-type tinea pedis
• Presence of serous exudate or pus
• Treatment with a topical antifungal in the past 2 weeks
• Treatment with a systemic antifungal in the past 4 weeks
• Concurrent immunosuppressive or antimicrobial therapy
• Liver disease
• Pregnancy or breastfeeding
• Use any other antifungal therapy during trial or within three months of starting the trial
• Known hypersensitivity to any ingredients of trial agents
• Patients with a current diagnosis of diabetes or neuropathy

Individual participant data (IPD) will not be shared outside the study team because this is a small study designed for internal evaluation of formulation performance and tolerability. Data will be presented only in aggregated, de-identified form in any publications or presentations.